Scholarlink

<p>Glucagon-like peptide-1 (GLP-1) is a hormone mainly produced by intestinal L cells after meal, and its main functions include enhancing glucose-dependent insulin secretion, promoting insulin biosynthesis, inhibiting glucagon secretion, inhibiting gastrointestinal activity and regulating appetite. In recent years, GLP-1, besides its well-known hypoglycemic effects, has been shown to have beneficial effects in the cardiovascular field, but the precise molecular mechanism is not yet fully understood. GLP-1 receptor (GLP-1R) is a class B G-protein-coupled receptor (GPCR), which is widely distributed in the cardiovascular system. This review aims to summarize the GLP-1R dependent signaling pathways in GLP-1 cardiovascular protection and related researches, such as the GLP-1R structure, distribution and expression. Moreover, we also discussed the development of GLP-1R agonist (GLP-1RA) therapies in cardiovascular field.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Glucagon-like Peptide-1 Receptor Dependent Signaling in Cardiovascular Health and Disease: A Mini-review

  • 期刊论文

  • 发表日期：

    2026年2月22日

查看全文
  • Meng-piao Lin,
  • Bing-jie Xue,
  • Xiao-jie Bai

摘要

Glucagon-like peptide-1 (GLP-1) is a hormone mainly produced by intestinal L cells after meal, and its main functions include enhancing glucose-dependent insulin secretion, promoting insulin biosynthesis, inhibiting glucagon secretion, inhibiting gastrointestinal activity and regulating appetite. In recent years, GLP-1, besides its well-known hypoglycemic effects, has been shown to have beneficial effects in the cardiovascular field, but the precise molecular mechanism is not yet fully understood. GLP-1 receptor (GLP-1R) is a class B G-protein-coupled receptor (GPCR), which is widely distributed in the cardiovascular system. This review aims to summarize the GLP-1R dependent signaling pathways in GLP-1 cardiovascular protection and related researches, such as the GLP-1R structure, distribution and expression. Moreover, we also discussed the development of GLP-1R agonist (GLP-1RA) therapies in cardiovascular field.